Literature DB >> 29070526

Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma.

Yun-Fan Sun1, Wei Guo2, Yang Xu1, Yin-Hong Shi1, Zi-Jun Gong1, Yuan Ji3, Min Du3, Xin Zhang1, Bo Hu1, Ao Huang1, George G Chen4, Paul B S Lai4, Ya Cao5, Shuang-Jian Qiu1, Jian Zhou1,6, Xin-Rong Yang7, Jia Fan7,6.   

Abstract

Purpose: The spatial heterogeneity of phenotypic and molecular characteristics of CTCs within the circulatory system remains unclear. Herein, we mapped the distribution and characterized biological features of CTCs along the transportation route in hepatocellular carcinoma (HCC).Experimental Design: In 73 localized HCC patients, blood was drawn from peripheral vein (PV), peripheral artery (PA), hepatic veins (HV), infrahepatic inferior vena cava (IHIVC), and portal vein (PoV) before tumor resection. Epithelial and mesenchymal transition (EMT) phenotype in CTCs were analyzed by a 4-channel immunofluorescence CellSearch assay and microfluidic quantitative RT-PCR. The clinical significance of CTCs from different vascular sites was evaluated.
Results: The CTC number and size gradient between tumor efferent vessels and postpulmonary peripheral vessels was marked. Tracking the fate of CTC clusters revealed that CTCs displayed an aggregated-singular-aggregated manner of spreading. Single-cell characterization demonstrated that EMT status of CTCs was heterogeneous across different vascular compartments. CTCs were predominantly epithelial at release, but switched to EMT-activated phenotype during hematogeneous transit via Smad2 and β-catenin related signaling pathways. EMT activation in primary tumor correlated with total CTC number at HV, rather than epithelial or EMT-activated subsets of CTCs. Follow-up analysis suggested that CTC and circulating tumor microemboli burden in hepatic veins and peripheral circulation prognosticated postoperative lung metastasis and intrahepatic recurrence, respectively.Conclusions: The current data suggested that a profound spatial heterogeneity in cellular distribution and biological features existed among CTCs during circulation. Multivascular measurement of CTCs could help to reveal novel mechanisms of metastasis and facilitate prediction of postoperative relapse or metastasis pattern in HCC. Clin Cancer Res; 24(3); 547-59. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29070526     DOI: 10.1158/1078-0432.CCR-17-1063

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.

Authors:  Yuan Cheng; Lei Luo; Juqiang Zhang; Mantian Zhou; Yujun Tang; Guolin He; Yishi Lu; Zhong Wang; MingXin Pan
Journal:  J Gastrointest Surg       Date:  2019-02-25       Impact factor: 3.452

Review 2.  EUS-Guided Portal Venous Sampling of Circulating Tumor Cells.

Authors:  Christopher G Chapman; Irving Waxman
Journal:  Curr Gastroenterol Rep       Date:  2019-12-07

Review 3.  2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

Review 4.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.

Authors:  Vincent L Chen; Dabo Xu; Max S Wicha; Anna S Lok; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-11       Impact factor: 11.382

Review 5.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

Review 6.  Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells.

Authors:  Laura Keller; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2019-08-27       Impact factor: 60.716

Review 7.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

Review 8.  Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.

Authors:  Joseph C Ahn; Pai-Chi Teng; Pin-Jung Chen; Edwin Posadas; Hsian-Rong Tseng; Shelly C Lu; Ju Dong Yang
Journal:  Hepatology       Date:  2021-01-18       Impact factor: 17.425

Review 9.  Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches.

Authors:  Renumathy Dhanasekaran
Journal:  Semin Liver Dis       Date:  2021-01-14       Impact factor: 6.115

Review 10.  Metastasis Prevention: Focus on Metastatic Circulating Tumor Cells.

Authors:  Maxim E Menyailo; Ustinia A Bokova; Elena E Ivanyuk; Anna A Khozyainova; Evgeny V Denisov
Journal:  Mol Diagn Ther       Date:  2021-07-21       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.